We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Acadia Hit With Securities Suit Over Drug Linked To Deaths

Law360 (July 20, 2018, 10:09 PM EDT) -- An Acadia Pharmaceuticals Inc. shareholder slapped the biopharmaceutical company with a putative securities fraud class action in California federal court Thursday, claiming the company inflated its stock price by hiding safety risks and downplaying reports of deaths connected to its treatment for hallucinations and delusions.

Investor plaintiff James Staublein filed his suit on behalf of a proposed class of persons and entities that acquired Acadia securities between April 29, 2016 — when the company announced its flagship drug Nuplazid was approved by the U.S. Food and...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Staublein v. Acadia Pharmaceuticals Inc. et al


Case Number

3:18-cv-01647

Court

California Southern

Nature of Suit

850(Securities/Commodities)

Judge

Judge Roger T. Benitez

Date Filed

July 19, 2018

Law Firms

Companies

Government Agencies

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.